Table 2.

Predictors of sofosbuvir-based therapy prescription (N= 1,284)

Predictors	Univariate Odds Ratio (95% CI)	Univariate p-value	Adjusted Odds Ratio (95% CI)	Adjusted p-value
Age
18–29	0.97 [0.51 – 1.88]	0.94	1.01 [0.49 – 2.07]	0.98
30–39	0.74 [0.39 – 1.40]	0.36	0.75 [0.39 – 1.47]	0.40
40–49	0.96 [0.60 – 1.52]	0.85	0.99 [0.61 – 1.60]	0.95
50–59	Reference		Reference
60–89	1.21 [0.66 – 2.23]	0.54	0.97 [0.51 – 1.85]	0.93
Male	1.18 [0.79 – 1.75]	0.43	1.16 [0.77 – 1.77]	0.48
Race/Ethnicity
White	Reference		Reference
Black	0.74 [0.48 – 1.13]	0.16	0.68 [0.43 – 1.07]	0.10
Latino	0.99 [0.52 – 1.87]	0.96	0.71 [0.33 – 1.52]	0.38
Asian	1.87 [0.61 – 5.70]	0.27	1.03 [0.29 – 3.64]	0.96
Other/Unknown	1.43 [0.69 – 2.96]	0.34	1.00 [0.43 – 2.32]	0.99
Insurance
Public	Reference		Reference
Private	1.34 [0.88 – 2.04]	0.17	1.31 [0.85 – 2.02]	0.21
Health Safety Net	1.32 [0.77 – 2.28]	0.32	1.27 [0.72 – 2.23]	0.41
Other/Unknown	0.52 [0.07 – 3.91]	0.52	0.53 [0.07 – 4.04]	0.54
HIV status
HIV-uninfected or unknown HIV statusa	Reference		Reference
HIV-infected	2.07 [0.94 – 4.53]	0.07	2.08 [0.94 – 4.65]	0.07
Birth place
US	Reference		Reference
Non US	1.68 [1.10 – 2.57]	0.02	1.67 [0.93 – 2.99]	0.08
Number of clinical visitsb (≥10 v. <10)	1.34 [0.92 – 1.94]	0.13	1.40 [0.96 – 2.06]	0.08
FIB 4
≤3.25	Reference		Reference
>3.25	1.81 [1.18 – 2.77]	0.01	1.66 [1.05 – 2.64]	0.03

HIV: Human Immunodeficiency Virus; US: United States; FIB 4: Fibrosis 4. This analysis controls for age, gender, ethnicity, insurance type, birthplace, number of clinical visits, and FIB-4 index.

^aHIV status was determined by HIV testing results or International Classification of Diseases (ICD)-9 code on the problem list. Individuals who did not have HIV testing performed were listed as unknown status

^bNumber of clinical visits during the one-year period evaluated.